Light: A new Masada medical thriller coming this summer

Leonard Zwelling

Dr. Zwelling is a board-certified internist and medical oncologist. He was trained at Duke University, Duke Medical School and Duke Hospital after which he completed his oncology training at the National Cancer Institute. He started his research career at NCI and in 1984 moved to The University of Texas MD Anderson Cancer Center where he rose to the rank of Professor of Medicine and Pharmacology. He returned to business school at the University of Houston, graduating in 1993. He then gravitated to research administration.

A Comma, Semi-colon, Or Hyphen: It’s Hillary’s Choice

A Comma, Semi-colon, Or Hyphen: It’s Hillary’s Choice By Leonard Zwelling          Both major American political parties are undergoing dramatic transitions right before our eyes. The difference is that the GOP has got it done and the Dems have not.          That Donald Trump has become the presumptive nominee of the Republican Party for President […]

A Comma, Semi-colon, Or Hyphen: It’s Hillary’s Choice Read More »

“Aiming High”-A True Change In The Battle Against Cancer Or A Likely Description Of The Conditions of The Authors Of The New England Journal Of Medicine Editorial (374:1901-1904, 2016)? By Leonard Zwelling          The May 19 edition of the NEJM leads with a guest editorial by Douglas Lowy and Francis Collins, the current leaders of

Read More »

The Plea To Be Allowed To Make It Up As You Go Along: The Quandary of the N=1 Clinical Trial

The Plea To Be Allowed To Make It Up As You Go Along: The Quandary of the N=1 Clinical Trial By Leonard Zwelling http://www.nytimes.com/2016/05/15/magazine/oncologist-improvisation.html?em_pos=large&emc=edit_ma_20160513&nl=magazine&nlid=11039602&ref=headline&te=1          This Sunday’s NY Times Magazine is devoted to Cancer—that’s with a capital C.          This article by Pulitzer Prize winning author and oncologist Sid Mukherjee outlines the vexing puzzle faced by

The Plea To Be Allowed To Make It Up As You Go Along: The Quandary of the N=1 Clinical Trial Read More »